Pub. Date : 2012 Jan
PMID : 22031231
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. | Vinorelbine | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 2 | INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. | Vinorelbine | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 3 | INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. | Vinorelbine | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 4 | CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation. | Vinorelbine | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |